Skip to content
Facebook Twitter Linkedin Pinterest Youtube Instagram

Bridging the Gap Between Participants and Clinical Trials

  • Who We Are
  • FAQs
  • Jobs
  • Blog
  • Contact
  • Member’s Login
  • Who We Are
  • FAQs
  • Jobs
  • Blog
  • Contact
  • Member’s Login
  • Clinical Trials
    • Recruiting
    • Active, Not Recruiting
    • Closed: follow-up continuing
    • Closed: follow-up complete
    • Completed
  • Trial Sites
  • Join Our Community
  • Clinical Trials
    • Recruiting
    • Active, Not Recruiting
    • Closed: follow-up continuing
    • Closed: follow-up complete
    • Completed
  • Trial Sites
  • Join Our Community

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Read More »

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Read More »

Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Read More »

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Read More »

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

Read More »

Gilead Sustained Virologic Response (SVR) Registry

Read More »

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

Read More »

Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial

Read More »

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

Read More »

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Read More »
« Previous Next »

AustralianClinicalTrials.com

  • Who We Are
  • FAQs
  • Blog
  • Contact Us
  • Who We Are
  • FAQs
  • Blog
  • Contact Us

Community

  • Clinical Trials
  • Trial Sites
  • Ethics Committees
  • Clinical Trials
  • Trial Sites
  • Ethics Committees

Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.

Francis of Assisi

Copyright © 2025 Australian Clinical Trials. Terms of Use  /  Privacy Policy

Facebook Twitter Linkedin Pinterest Youtube Instagram